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Background. Impairments of endocrine system may be associated with exposure to perfluorinated compounds that are able to
bind nuclear receptors, including the peroxisome proliferator-activating receptors. Aim of this study was to assess perfluorooctane
sulfonate and perfluorooctanoic acid concentrations in children and adolescents at the onset of type 1 diabetes compared to healthy
controls. Methods. Forty-four children and adolescents were recruited and subdivided into two groups: (A) 25 subjects with type
1 diabetes and (B) 19 healthy controls. Perfluorinated compounds were measured using high performance liquid chromatography
with electrospray ionization tandemmass spectrometry. Nonparametric statistical analysis was performed.Results. Perfluorooctane
sulfonate concentrations were significantly higher in patients with type 1 diabetes compared to controls (1.53 ± 1.50 versus 0.55 ±
0.15 ng/mL, resp.; 𝑝 < 0.001). Multivariate linear regression analysis identified lipid levels as significant predictive factors for
perfluorooctane sulfonate levels. Conclusions. Our data suggests that higher serum levels of perfluorooctane sulfonate may be
considered a biomarker of exposure and susceptibility to develop type 1 diabetes.
1. Introduction
Perfluorinated compounds (PFCs) are chemical products
extensively investigated for their environmental ubiquity and
toxicity. Two of the PFCs of most concern are the eight-
carbon-chain perfluorooctane sulfonate (PFOS) and perfluo-
rooctanoic acid (PFOA), which are synthetically produced or
derived by the metabolism of other PFCs and are widespread
since used in industrial and consumer products [1]. PFOS and
PFOA are both lipo- and hydrophobic and are characterized
by a high potential to bioaccumulate after absorption, binding
serum proteins rather than storing in lipids [2]. They are
slowly metabolized and their half-life in human blood serum
has been estimated to be more than 5 years for PFOS and
around 4 years for PFOA [3]. This extremely long half-life in
humans contrasts with the relatively rapid elimination seen in
animalmodels drawing attention to potential risks for human
health [2].
PFCs are globally found in human tissues, as humans
are daily exposed to contaminated food, water, and air,
independently to industries nearby [4, 5]. Human biomon-
itoring of the general population in different countries has
shown that PFOS and PFOA may also be found in breast
milk, liver, seminal fluid, and umbilical cord blood [5–7].
However, in spite of the widespread exposure to PFCs, there
are considerable individual differences in exposure levels [8].
The effects of exposure to PFOS and/or PFOA on human
health have not been fully ascertained yet, but by extrapo-
lating animal data they seem to be related to pathological
conditions in exposed organisms including enlargement of
the liver, dyslipidemia, neurobehavioral toxicity, immune
system toxicity, reduced body weight, reproductive toxicity,
and hormonal effects [5]. Specifically, alterations in hepatic
metabolism and function have been attributed to the ability
of PFOS and PFOA to bind nuclear receptors, including the
peroxisome proliferator-activating receptor-𝛼 (PPAR𝛼) [9]
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and to disrupt serum protein ligand binding [10], acting as
potential endocrine disruptors [11] although it is still unclear
whether these animal-based evidences can be extrapolated to
humans.
Compared with effects seen in animals, human studies
have reported different associations between PFCs and both
lipid levels [12, 13] and the endocrine system, especially thy-
roid function [12]. Olsen and Zobel [12] measured PFOA
concentrations in 506male fluorochemical production work-
ers demonstrating no association with total cholesterol (TC),
low-density lipoprotein cholesterol (LDL), hepatic enzymes,
or thyroid hormones. Another study including 12476 children
and adolescents showed that PFOA was significantly asso-
ciated with increased TC and LDL, and PFOS was signifi-
cantly associated with increased TC, high-density lipoprotein
cholesterol (HDL), and LDL [13].
Both prenatal and childhood elevated exposure to PFCs
were linked to reduced humoral immune response to routine
immunizations in early childhood, suggesting an immune
system alteration [14, 15]. Children with high blood levels of
PFCs had lower antibody levels for diphtheria and tetanus
than children with lower PFC levels.The antibody loads were
likely too low to protect children against these infections [14].
Up to now no study exists investigating the potential
relationship between PFCs compounds exposure and devel-
opment of an endocrine-autoimmune disease in childhood
and adolescents. For this purpose, we studied a group of
children and adolescents at the onset of type 1 diabetes
(T1DM) compared to healthy controls who were consecu-
tively recruited during 2 years (2012-2013).
2. Methods
2.1. Study Population. We performed a case-control study at
the Pediatric Department of the University of Modena and
Reggio Emilia (Italy). Study subjects were 25 children and
adolescents enrolled at the onset of T1DM (3.15–13.1 years,
12 males; median glycohemoglobin 10.5%) and 19 healthy
subjects used as control group (1.88–13.6 years, 9 males).
Each subject included in the control group was referred
to our attention because of short stature; after appropriate
investigations, endocrine or other diseases were excluded. To
avoid confounding factors due to different PFCs exposure
each control was recruited at the same time (or +2 weeks)
of each T1DM onset. All subjects were native Italians and
residents in Modena or surrounding areas at least 5 years at
the time of their recruitment in the study. Participation and
enrollment included collection of auxological data together
with blood samples. Written informed consent was obtained
from all parents at the moment of recruitment in the study
and before data collection. The design of the study was
approved by the Ethics Committee of the University of
Modena and Reggio Emilia (Protocol number 1429CE).
2.2. Anthropometric Measurements. All patients underwent a
complete clinical history and physical examination including
anthropometric measurements that were performed by fully
trained examiners according to the Anthropometric Stan-
dardization Reference Manual [16]. Height was measured to
the nearest 0.1-cm with a calibrated wall-mounted stadiome-
ter (Harpenden, Crymych, UK) and weight was measured to
the nearest 0.1-kg with a calibrated scale. Body mass index
(BMI) was calculated by dividing weight in kg by height
squared (m2); 𝑧-score of BMI (𝑧-BMI) was calculated using
the appropriate Italian growth reference (ISPED Growth
Calculator).
2.3. Laboratory Methods. Clinical laboratory tests were per-
formed in each patient between 07.00 and 10.00 am, after a
12-hour overnight fast: leukocyte count (WBC), lymphocytes
count, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), creatinine, urea, TC, HDL, LDL, triglyc-
erides (TG), thyroid-stimulating hormone (TSH), PFOS, and
PFOA.
Serum samples (about 0.5mL) to assay PFCs were col-
lected and stored few days after T1DM was diagnosed.
Samples were kept frozen at −20∘C until analysis; precautions
were taken to avoid contamination. The analytical procedure
for PFOS and PFOA follows Governini et al. [17]. Concen-
trations of PFCs were measured using high performance
liquid chromatography (HPLC) with electrospray ionization
(ESI) tandem mass spectrometry. Analyte separation was
performed using a Finnigan Surveyor Plus HPLC System.
Chromatographic separation was achieved using a Betasil©
C18 column (Thermo Electron Corporation, San Jose, CA).
For quantitative determination, the HPLC system was inter-
faced to a Finnigan LTQ linear ion trap mass spectrometer
(Thermo 150 Electron Corporation, San Jose, CA) operated
in negative electrospraymode. Instrumental parameters were
optimized to transmit the [M-H]-ion for all the analytes. The
repeatability and reproducibility were performed in triplicate
and were 85% and 90%, respectively. The limit of detection
for both PFOS and PFOAwas 0.4 ng/mL.The laboratory staff
was blinded to any information about the subjects.
2.4. Statistical Analysis. All results are reported as themean±
standard deviation (SD). Data were checked for normal
distribution using theKolmogorov-Smirnov test, so nonpara-
metric statistical analysis (STATISTICA software, StatSoft
Inc., Tulsa, OK, USA) was performed. Between-group and
gender comparisonswere evaluated using theMann-Whitney
𝑈 test while between-variable differences (PFOS and PFOA)
were analyzed through the Wilcoxon Matched Pairs Test.
Spearman’s correlation analysis was performed to assess the
linear association between PFOS or PFOA and age, 𝑧-BMI,
renal function, liver function, lipid profile, and TSH. The
association between potential predictors and levels of PFOS
or PFOA was evaluated using the following multivariate
linear regression model including age, 𝑧-BMI, TC, HDL, TG,
and LDL. Statistical significance was set at 𝑝 < 0.05.
3. Results
The description of the study population is given in Table 1.
Mean TC levels were significantly higher in T1DM
patients than in controls (183.7 ± 27.0 versus 170.1 ± 15.1mg/
dL, resp.; 𝑝 = 0.015), with 24% of values classified as
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Table 1: Anthropometric characteristics of study population.
Groups/auxological
data T1DM (𝑛 25) Controls (𝑛 19) 𝑝 value
Age (years) 0.001
Mean ± SD 8.04 ± 2.90 10.7 ± 2.77
Median 8.28 11.2
GM 7.46 10.1
Height (cm) 0.970
Mean ± SD 127.7 ± 17.4 128.0 ± 12.6
Median 132.0 131.9
GM 126.6 127.4
Weight (kg) 0.546
Mean ± SD 28.3 ± 9.92 29.5 ± 8.17
Median 28.0 29.2
GM 26.7 28.4
BMI (kg/m2) 0.356
Mean ± SD 16.9 ± 2.27 17.7 ± 2.78
Median 15.9 17.1
GM 16.8 17.5
𝑧-BMI 0.273
Mean ± SD 0.21 ± 0.94 0.01 ± 1.04
Median 0.00 −0.15
GM — —
BMI: body mass index; 𝑧-BMI: 𝑧-score body mass index; GM: geometric
mean; SD: standard deviation; SDS: standard deviation score; T1DM: type 1
diabetes.
acceptable (<170mg/dL). The lymphocyte count in T1DM
was significantly lower than in controls (2.28 ± 0.60 versus
2.95 ± 0.85migl/𝜇L, resp.; 𝑝 = 0.008) with no apparent
difference in WBC counts (Table 2). However, values were
always within the normal range.
PFOA concentrations were similar between T1DM and
control groups (0.53 ± 0.09 versus 0.50 ± 0.06 ng/mL, resp.;
𝑝 = 0.160) (Table 3 and Figure 1) while PFOS levels were sig-
nificantly higher in T1DM patients (1.53 ± 1.50 versus 0.55 ±
0.15 ng/mL, resp.; 𝑝 < 0.001) (Table 3 and Figure 2). All
values of PFOA and PFOS were above the lower limit of
detection (0.4 ng/mL) at that time. In T1DM patients PFOA
concentrations ranged from 0.46 to 0.83 ng/mL with median
values of 0.49 ng/mL, while PFOS concentrations ranged
from 0.48 to 6.68 ng/mL with median values of 0.95 ng/mL.
In the control group PFOA concentrations ranged from 0.45
to 0.67 ng/mLwithmedian values of 0.48 ng/mL, while PFOS
concentrations ranged from 0.47 to 0.93 ng/mL with median
values of 0.49 ng/mL.
Using the Wilcoxon Matched Pairs Test we found that
PFOA levels were significantly lower than PFOS ones in both
T1DM (𝑝 < 0.001) and control (𝑝 = 0.048) groups.
In T1DM group, when data were analyzed according
to gender, we did not find any difference in all analyzed
variables, specifically PFCs (data not shown).
In T1DM group analyzing data using Spearman’s correla-
tion test we found a significant negative association between
Table 2: Serum chemistry biomarkers and hematologic variables in
study population.
Group/biochemical
data
T1DM (𝑛 25) Controls (𝑛 19) 𝑝 value
TSH (𝜇IU/mL) 0.375
Mean ± SD 2.39 ± 0.98 2.03 ± 0.50
Median 2.24 1.98
GM 2.22 1.98
AST (U/L) 0.005
Mean ± SD 23.2 ± 3.09 35.3 ± 23.8
Median 23.0 27.5
GM 22.9 31.0
ALT (U/L) 0.110
Mean ± SD 18.1 ± 4.90 25.0 ± 15.1
Median 18.0 24.5
GM 17.3 21.4
TC (mg/dL) 0.015
Mean ± SD 183.7 ± 27.0 170.1 ± 15.1
Median 188.0 170.5
GM 181.6 169.5
HDL-C (mg/dL) 0.622
Mean ± SD 62.7 ± 13.4 62.3 ± 8.05
Median 62.0 61.5
GM 61.1 61.9
TG (mg/dL) 0667
Mean ± SD 65.0 ± 22.1 57.0 ± 9.85
Median 60.0 56.0
GM 61.9 56.3
LDL-C (mg/dL) 0.597
Mean ± SD 101.1 ± 29.8 102.0 ± 12.1
Median 101.0 102.0
GM 96.8 101.3
Urea (mg/dL) 0.112
Mean ± SD 32.1 ± 7.34 28.3 ± 4.88
Median 34.0 28.0
GM 31.3 28.0
Creatinine (mg/dL) 0.631
Mean ± SD 0.60 ± 0.16 0.57 ± 0.11
Median 0.59 0.56
GM 0.59 0.57
WBC (migl/𝜇L) 0.453
Mean ± SD 6.59 ± 1.72 7.08 ± 1.89
Median 6.59 6.85
GM 6.39 6.87
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Table 2: Continued.
Group/biochemical
data
T1DM (𝑛 25) Controls (𝑛 19) 𝑝 value
Lymphocytes
(migl/𝜇L)
0.008
Mean ± SD 2.28 ± 0.60 2.95 ± 0.85
Median 2.12 3.00
GM 2.21 2.83
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GM: geo-
metric mean; HDL: high-density lipoprotein cholesterol; LDL: low-density
lipoprotein cholesterol; SD: standard deviation; TC: total cholesterol; TG:
triglycerides; T1DM: type 1 diabetes; TSH: thyroid-stimulating hormone.
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Figure 1: Serum concentration of PFOA (T1DM group compared
with control group: Mann-Whitney 𝑈 test 𝑝 = 0.160).
PFOS and TG levels (𝑟 = −0.50, 𝑝 = 0.010) and ALT levels
(𝑟 = −0.47, 𝑝 = 0.016) while a significant positive association
was demonstrated with creatinine values (𝑟 = 0.49, 𝑝 =
0.012). PFOA levels were positively correlated with AST (𝑟 =
0.42, 𝑝 = 0.036). Data for controls demonstrated a significant
positive association between PFOS levels and age (𝑟 = 0.50,
𝑝 = 0.035) and TSH (𝑟 = 0.57, 𝑝 = 0.012).
Finally, considering the whole study population, multi-
variate linear regression analysis allowed us to identify TC
(𝛽 = 0.82, 𝑝 = 0.040) and TG (𝛽 = −0.44, 𝑝 =
0.029) as predictive factors for PFOS levels; none of included
variables were demonstrated to be significant predictive
factors for PFOA concentrations. Age was shown to be the
only significant predictive factor for PFOS levels in T1DM
subjects (𝛽 = 0.43, 𝑝 = 0.036), while, in the control group,
regression analysis did not show statistically significance for
any predictive factor. No significant predictive factors were
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Figure 2: Serum concentration of PFOS (T1DM group compared
with control group: Mann-Whitney 𝑈 test 𝑝 < 0.001).
demonstrated for PFOA neither in T1DM nor in control
groups (Table 4).
4. Discussion
To the best of our knowledge, no study has yet investigated
the potential relationship between PFCs exposure and devel-
opment of autoimmune diseases in children and adolescents.
This is the first study about the presence of serum PFCs in
patients at T1DM onset compared to healthy controls.
We found that mean serum PFOS concentrations were
significantly higher in T1DM subjects than in controls. More-
over, PFOA levels were significantly lower than PFOS ones.
PFOA levels have been generally measured as slightly lower
than PFOS, with relevant differences in terms of frequency
among several studies, probably related to the huge variability
of detection methods. In the PERFORCE study [18], 17 par-
ticipating laboratories produced standardized serum cutoffs
that varied with a relative SD of 31.5%. One strength of our
study is the high sensitivity of the equipment we used, which
allowed us to determine PFOA concentrations in all the ana-
lyzed serum samples, even at extremely low concentrations.
Despite significantly lower PFOS levels our controls
showed a significant positive correlation between PFOS con-
centrations and chronological age; the same was not found
in patients with T1DM. The meaning of this correlation is
still unclear and will likely need to be interpreted within
the context of a better understanding of patterns of cumula-
tive exposure, environmental accumulation, and physiologic
metabolism of these chemicals across the life span.
Several studies have been conducted to investigate the
possible modes of action of PFOS. Induction of peroxisome
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Table 3: Serum concentration of PFOA and PFOS (ng/mL) in study population.
𝑁 Mean ± SD Median GM 𝑝 value Min Max 25th 75th 95% CI
PFOA (ng/mL) 0.160
T1DM 25 0.53 ± 0.10 0.49 0.52 0.46 0.83 0.48 0.55 0.07–0.13
Control 19 0.50 ± 0.06 0.48 0.50 0.45 0.67 0.46 0.50 0.05–0.10
PFOS (ng/mL) <0.001
T1DM 25 1.53 ± 1.51 0.95 1.09 0.48 6.68 0.50 1.84 1.18–2.10
Control 19 0.56 ± 0.16 0.49 0.54 0.47 0.93 0.48 0.50 0.12–0.23
GM: geometric mean; PFOA: perfluorooctanoic acid; PFOS: perfluorooctane sulfonate; SD: standard deviation; T1DM: type 1 diabetes.
Table 4: Results of multivariate linear regression analysis on PFOS and PFOA levels in serum.
PFOS PFOA
All population (𝑛 44) T1DM (𝑛 25) Controls (𝑛 19) All population (𝑛 44) T1DM (𝑛 25) Controls (𝑛 19)
SE 1.21 1.35 0.15 0.08 0.09 0.06
𝑅 (𝑅2) 0.43 (0.18) 0.63 (0.40) 0.64 (0.41) 0.35 (0.12) 0.50 (0.26) 0.63 (0.39)
𝑝 value 0.269 0.117 0.332 0.549 0.435 0.380
Intercept
Coeff. 1.01 2.84 0.41 0.71 0.85 0.42
SE 1.97 2.58 0.50 0.14 0.18 0.21
𝑝 value 0.613 0.285 0.430 <0.001 <0.001 0.069
Age
Coeff. 0.13 0.43 0.17 −0.24 −0.07 −0.20
SE 0.16 0.19 0.25 0.16 0.21 0.25
𝑝 value 0.404 0.035 0.523 0.143 0.751 0.449
BMI 𝑧-score
Coeff. −0.11 −0.21 −0.01 0.02 −0.23 0.43
SE 0.17 0.20 0.29 0.17 0.22 0.29
𝑝 value 0.507 0.306 0.968 0.889 0.322 0.172
TC
Coeff. 0.82 0.02 0.44 −0.20 −0.86 0.12
SE 0.38 0.60 0.70 0.39 0.67 0.72
𝑝 value 0.040 0.972 0.544 0.614 0.219 0.864
HDL-C
Coeff. −0.34 −0.14 −0.70 −0.10 0.09 −0.20
SE 0.24 0.38 0.39 0.25 0.42 0.39
𝑝 value 0.172 0.719 0.097 0.692 0.834 0.618
TG
Coeff. −0.44 −0.47 0.47 −0.14 −0.07 0.09
SE 0.19 0.27 0.29 0.20 0.30 0.30
𝑝 value 0.029 0.099 0.141 0.496 0.804 0.753
LDL-C
Coeff. −0.74 −0.04 −0.24 0.22 0.75 0.19
SE 0.37 0.61 0.62 0.38 0.68 0.63
𝑝 value 0.054 0.946 0.706 0.559 0.288 0.765
𝑧-BMI: 𝑧-score body mass index; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; PFOA: perfluorooctanoic acid; PFOS:
perfluorooctane sulfonate; SE: standard error; TC: total cholesterol; TG: triglycerides; T1DM: type 1 diabetes.
proliferation and associated peroxisomal enzymes [19], acti-
vation of nuclear receptors [9], interference in lipid metab-
olism and decreases in serum cholesterol [10, 12, 13], and
alterations in thyroid hormone homeostasis [20, 21] have all
been investigated as possible modes of action. However, at
the moment, the mechanisms of action related to the toxicity
of PFOS are still not clearly understood.
T1DM is an autoimmune disease driven by the activa-
tion of T lymphocytes, mainly CD8+, against pancreatic 𝛽-
cells. The lymphocytes count in our patients with diabetes
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was significantly lower than in control, with no apparent
change in the number of circulating WBC. The worldwide
increasing incidence of T1DM in childhood remains unex-
plained. Environmental chemicals that can act as endocrine
disruptors may affect the development and function of the
immune system in ways that could promote autoimmu-
nity and thereby contribute to the development of T1DM
[22].
The specific role of PPARs in PFCs-immunotoxicity is still
a matter of debate, and it is unclear whether or not there is
a direct effect on immune cells. In mice, PFOS and PFOA
probably exert an influence on the immune system, acti-
vating innate immunity and suppressing adaptive immune
responses but the cause and significance of this activation of
immune system by PFCs remain to be determined [23]. On
the other hand, various leukocyte populations express PPARs
and therefore a role in immune response of lymphocytes
is suggested for this transcription factor [24]. PFCs directly
affected immune cell activation and reduced cytokine pro-
duction (both pro- and anti-inflammatory) through different
mechanisms as demonstrated by Corsini et al. [25].The exact
role of PPARs in PFCs-immunotoxicity is complex with some
effects resulting from a PPAR-mediated mechanism, while
other effects result from PPAR-independent mechanism.
Despite the fact that we observed that T1DM patients had
significantly higher levels of TC compared to controls we
only found a negative correlation between serum PFOS and
TG. Considering the whole study population, multivariate
linear regression analysis allowed us to identify lipid profile
as main predictor factor of PFOS levels. Probably PFCs bind
to the PPARs interfering with lipid metabolism because of
their ability to act as PPAR agonists, as previously suggested
from animal studies [19]. Few is known about how these
chemicals interfere with the human biological mechanisms,
but epidemiologic studies have consistently shown that PFCs,
mainly PFOA, were positively associated with lipid profile
[12, 26–28] while others have not had significant evidence
to support the association with cholesterol outcomes with
PFOA and PFOS [29]. Frisbee et al. [13] reported for the first
time in children and adolescents that increasing PFOA and
PFOS quintiles were positively associated with an increased
risk of abnormal TC and LDL but not TG.
A limitation of our study is the small sample size. How-
ever, if associations reported in this paper are etiologic, expo-
sure prevention would become important to reduce onset
of T1DM and the long-term health consequences. Moreover,
studying potential health consequences of an environmental
exposure in children and adolescents may provide greater
insight because these groups likely have fewer factors con-
founding underlying associations compared with adults.
Finally, given possible differences in physiologic processes
owing to developmental changes in children and adolescents,
toxic effects may be different compared with those observed
in adults.
In conclusion, our results suggest that high serum levels
of PFOS may be considered a biomarker of susceptibility to
develop TIDM.
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